1. Type of Estimate and Analysis ⊠ Original □ Updated □Corrected	2. Date
	04/18/2019
3. Administrative Rule Chapter, Title and Number (and Clearinghouse Number if applicable) DHS 115, relating to screening of newborns for congenital and metabolic disorders.	
4. Subject Screening of newborns for congenital and metabolic disorders.	
5. Fund Sources Affected	6. Chapter 20, Stats. Appropriations Affected $N\!/\!A$
7. Fiscal Effect of Implementing the Rule No Fiscal Effect Increase Existing Revenues Indeterminate Decrease Existing Revenues	 ☑ Increase Costs □ Decrease Costs □ Could Absorb Within Agency's Budget
8. The Rule Will Impact the Following (Check All That Apply)	
 ☐ State's Economy ☐ Local Government Units ☐ Public Utility Rate Payers 	
Cocar Government on its Public of inty Rate Payers Small Businesses (if checked, complete Attachment A)	
9. Estimate of Implementation and Compliance to Businesses, Local Governmental Units and Individuals, pers. 227.137(3)(b)(1).	
\$65,000 implementation cost for Wisconsin State Lab of Hygiene (WSLH)	
10. Would Implementation and Compliance Costs Businesses, Local Governmental Units and Individuals Be \$10 Million or more Over Any 2-year Period, pers. 227.137(3)(b)(2)?	
11. Policy Problem Addressed by the Rule As provided in s. 253.13 (1), Stats., ch. DHS 115 specifies the congenital disorders for which newborns must be screened	
by means of a blood sample shortly after birth and tested by the WSLH. 2013 Wisconsin Act 135 modified s. 253.13 (1)	
Stats., relating to infant blood tests so the required screening may be performed by methods in addition to blood testing. The Department intends to revise ch. DHS 115 to conform the rule language to s. 253.13, Stats. The proposed rule order	
adds Carnitine Palmitoyltransferase IA (CPT IA) deficiency and Spinal Muscular Atrophy (SMA) as conditions for	
which newborns must be tested.	
12. Summary of the Businesses, Business Sectors, Associations Representing Business, Local Governmental Units, and Individuals	
that may be Affected by the Proposed Rule that were Contacted for Comments. From 3/25/2019 - 04/08/2019, the Department solicited information and advice from individuals, businesses,	
associations representing businesses, and local governmental units who may be affected by the proposed rule for use in	
analyzing and determining the economic impact that the rules would have on businesses, individuals, public utility rate	
payers, local governmental units, and the state's economy as a whole. 27 public comments were received, all in support	
of adding CPT IA and SMA as conditions for which newsborns must be tested.	
13. Identify the Local Governmental Units that Participated in the Development of this EIA.	
None.	
14. Summaryof Rule's Economic and Fiscal Impacton Specific Businesses, Business Sectors, Public Utility Rate Payers, Local Governmental Units and the State's Economyas a Whole (Include Implementation and Compliance Costs Expected to be Incurred)	
There are no costs for the implementation of screening for CPT IA. For the implementation of screening for SMA, there	
is a cost of \$1 per infant screened per approximately 65,000 WI births annually. The additional cost is attributed to	
	WI births annually. The additional cost is attributed to
WSLH operational costs. The cost for follow up counseling i	WI births annually. The additional cost is attributed to

15. Benefits of Implementing the Rule and Alternative(s) to Implementing the Rule

There are no alternatives to rulemaking. Preservation of the public health and welfare requires screening newborns for CPT IA and SMA

16. Long Range Implications of Implementing the Rule

Long range implications include decreasing negative health outcomes for infants wih CPT IA and SMA. Early interventions are available and have been shown, in well-designed studies, to be safe and effective in preventing or ameliorating serious health consequences stemming from a delayed or missed diagnosis of these disorders.

17. Compare With Approaches Being Used by Federal Government

There appears to be no existing or proposed federal regulations that address the activities to be regulated by the proposed rules.

18. Compare With Approaches Being Used by Neighboring States (Illinois, Iowa, Michigan and Minn esota) Illinois:

Illinois 410 ILCS 240/1.10 (b) 77 Ill. Adm. Code 661.10 Responsibility for Screening explains that a Genetic and Metabolic Diseases Advisory Committee will recommend to the Department when an additional disorder should be added to the screening panel. Implementation of the Department's determination is subject to that determination's adoption by rule. This process is similar to Wisconsin's procedure for adding a disorder.

Illinois does screen for CPT1A, but is not currently screening for SMA. However, legislation was passed to screen for SMA, but a testing method is still under development.

Iowa:

Iowa Code s. 136A.5A 641—4.3(136A) Iowa newborn screening program (INSP). This program provides comprehensive newborn screening services for hereditary and congenital disorders for the state. 4.3(1) Newborn screening policy. All newborns and infants born in the state of Iowa shall be screened for all congenital and inherited disorders specified by the center and approved by the state board of health.

Iowa does not currently screen for CPT IA or SMA, however, their Congenital and Inherited Disorders Advisory Committee may vote on whether to recommend the addition of SMA to the panel in January, 2019 depending on the availability and outcome of the needs assessment for adding SMA.

Michigan:

Under Michigan statute, MCLS, s. 333.5431 (1) (i) refers to CPT IA generally as "other treatable but otherwise disabling conditions as designated by the department." The Michigan Department of Community Health website lists all (55) of the disorders included in their screening panel which includes CPT IA. [Michigan's legislatively-mandated committee voted to add SMA to Michigan's NBS panel and are currently working through their approval process]. MCL 333.5430 established a legislatively-mandated advisory committee that is charged with meeting annually. This committee has the authority to add disorders to the NBS panel and approve fee increases associated with adding a disorder. Michigan has been screening for CPT IA since 2005 but does not currently screen for SMA. However, their legislatively-mandated committee voted to add SMA to Michigan's NBS panel and are working through their approval process.

Minnesota:

Minn. Stats. s. 144.125 TESTS OF INFANTS FOR HERITABLE AND CONGENITAL DISORDERS. Subdivision 1. Duty to perform testing. (a) It is the duty of (1) the administrative officer or other person in charge of each institution caring for infants 28 days or less of age, (2) the person required in pursuance of the provisions of section 144.215, to register the birth of a child, or (3) the nurse midwife or midwife in attendance at the birth, to arrange to have administered to every infant or child in its care tests for heritable and congenital disorders according to subdivision 2 and rules prescribed by the state commissioner of health. Subd. 2. Determination of tests to be administered. Minnesota currently screens for both CPT IA since 2003 and SMA since 2018.

19. Contact Name

20. Contact Phone Number

Gary Kirk

608-266-5818

This document can be made available in alternate formats to individuals with disabilities upon request.

ATTACHMENT A

1. Summary of Rule's Economic and Fiscal Impact on Small Businesses (Separately for each Small Business Sector, Include Implementation and Compliance Costs Expected to be Incurred)

2. Summary of the data sources used to measure the Rule's impact on Small Businesses

3. Did the agency consider the following methods to reduce the impact of the Rule on Small Businesses?

Less Stringent Compliance or Reporting Requirements

Less Stringent Schedules or Deadlines for Compliance or Reporting

Consolidation or Simplification of Reporting Requirements

Establishment of performance standards in lieu of Design or Operational Standards

Exemption of Small Businesses from some or all requirements

Other, describe:

4. Describe the methods incorporated into the Rule that will reduce its impact on Small Businesses

5. Describe the Rule's Enforcement Provisions

6. Did the Agency prepare a Cost Benefit Analysis (if Yes, attach to form)